Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
about
Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.Current and emerging factor VIII replacement products for hemophilia A.Novel approaches to hemophilia therapy: successes and challenges.Novel therapies and current clinical progress in hemophilia A.Emerging therapies for hemophilia: controversies and unanswered questions.Extended Half-Life Factor VIII and Factor IX Preparations.
P2860
Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
@en
Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
@nl
type
label
Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
@en
Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
@nl
prefLabel
Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
@en
Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
@nl
P2093
P2860
P356
P1476
Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
@en
P2093
I Pabinger
L A Michaels
L H Poulsen
M E Eyster
M Lederman
M T Reding
P2860
P304
P356
10.1111/JTH.13597
P577
2016-12-19T00:00:00Z